Skip to main content
Vaginal infection — not an STI (endogenous overgrowth of normal flora) Curable

Vaginal yeast infection testing

A vaginal yeast infection (vulvovaginal candidiasis, or VVC) is one of the most common reasons people visit a gynecologist — about <strong>three in four women</strong> will have at least one in their lifetime. It is caused by an overgrowth of <em>Candida</em>, a fungus that normally lives in the body, and it is <strong>not a sexually transmitted infection</strong>. OTC antifungal medications clear most cases within days, but a first episode or stubborn recurrence should be confirmed by a clinician: bacterial vaginosis, trichomoniasis, and chlamydia look similar and need completely different treatment. Studies show that fewer than one-third of women who self-treat for a presumed yeast infection actually have one.

Lifetime prevalence
~75%
of women get at least one vaginal yeast infection in their lifetime; ~45% get two or more
Self-diagnosis accuracy
<35%
Fewer than one-third of women who self-treat for a yeast infection have confirmed VVC — symptoms overlap with BV and STIs
OTC treatable
Yes
Most uncomplicated cases clear with antifungal cream, suppository, or a single 150 mg fluconazole pill
Recurrent VVC
5% of women
4+ confirmed episodes per year; requires culture, species ID, and 6-month maintenance therapy

Where to get tested

Find vaginal yeast infection testing near you

Choose your test and enter your city — we'll take you straight to local vaginal yeast infection testing: nearby clinics and labs, prices, hours and county rates.

Test from home

At-home STD testing in the U.S.

if you'd rather skip the trip, an at-home kit ships to the U.S., you collect the sample privately, and mail it back to a CLIA-certified lab. Results come online in days, with a clinician available if anything is positive. Same labs as a clinic, no waiting room — and you can read how accurate at-home STD tests are before you order.

Want a free option first? The CDC-supported TakeMeHome program mails free at-home HIV self-test kits — and, in many areas, free STI kits — to your door, with no insurance or payment needed. The paid kits below add broader panels and faster turnaround.

  • Best range — couples & full panels

    myLAB Box

    $79 & up

    Screens for:
    Up to 14 infections — incl. HIV, syphilis, chlamydia, gonorrhea, hepatitis & herpes
    Sample:
    Self-collect: swab, urine, finger-prick
    Results:
    2–5 days, online
    • Free phone consult if positive
    • CLIA-certified labs
    • Couples & subscription options
    • Discreet packaging
    Order online myLAB Box review

  • Best for simplicity & support

    LetsGetChecked

    $89 & up

    Screens for:
    5–6 common STIs incl. chlamydia, gonorrhea, HIV, syphilis & trichomoniasis
    Sample:
    Finger-prick + urine/swab
    Results:
    2–5 days, online
    • 24/7 nurse support
    • Prescription for positives
    • CLIA-certified labs
    • Free shipping both ways
    Order online LetsGetChecked review

  • Best value — single tests

    Everlywell

    $49 & up

    Screens for:
    Chlamydia & gonorrhea, up to a 6-test panel adding HIV, syphilis, trichomoniasis & hep C
    Sample:
    Finger-prick + swab
    Results:
    Days, online
    • Telehealth visit if positive
    • CLIA-certified labs
    • HSA/FSA eligible
    • Subscription savings
    Order online Everlywell review

Every kit uses CLIA-certified labs. At-home testing is for screening; a reactive result should be confirmed and treated by a clinician. Prices and panels shown are illustrative and change often — confirm current details on the provider's site.

Understanding vaginal yeast infection

What is vaginal yeast infection?

A vaginal yeast infection — medically termed vulvovaginal candidiasis (VVC) — is caused by an overgrowth of Candida albicans, a fungus that normally lives in small, harmless amounts in the vagina, gut, mouth, and skin. When internal or environmental factors disrupt the balance of the vaginal microbiome, Candida multiplies beyond its normal threshold and triggers the classic symptoms: intense vulvovaginal itching, burning, swelling, and a thick white discharge that many describe as resembling cottage cheese. Approximately 75–90% of vaginal yeast infections are caused by C. albicans; the remainder involve non-albicans species such as C. glabrata, C. tropicalis, and C. parapsilosis, which behave differently in important ways — they may not form hyphae visible on KOH microscopy and are frequently resistant to standard fluconazole treatment.

A vaginal yeast infection is not a sexually transmitted infection. Candida overgrowth is driven by internal and environmental triggers — antibiotics that disrupt the protective Lactobacillus-dominant flora, pregnancy (elevated estrogen increases vaginal glycogen that feeds Candida), uncontrolled diabetes (high blood glucose is a direct fungal growth medium), immunosuppression, hormonal contraceptives, tight or synthetic undergarments, and warm humid conditions — not sexual contact. That said, sexual activity can occasionally disturb vaginal flora and trigger an episode, and partners can occasionally be affected (male partners can develop penile candidiasis, or balanitis, with an estimated risk of ~15% after unprotected sex with someone who has an active infection).

The critical clinical issue is diagnostic accuracy. Yeast infections are the second most common cause of vaginal symptoms after bacterial vaginosis, yet studies consistently show fewer than one-third of women who self-treat for a presumed yeast infection actually have one (Ferris et al., Obstetrics & Gynecology, 2002). The most common misidentification is BV — which presents with discharge and odor but requires antibiotics, not antifungals. Trichomoniasis, chlamydia, and gonorrhea can also produce vaginal discomfort. Self-treating the wrong condition with an OTC antifungal delays correct diagnosis, may foster antifungal resistance, and allows a real STI to go untreated.

A first episode of symptoms, any recurrence that follows an atypical pattern, a case that does not resolve with OTC treatment, or any situation where an STI cannot be ruled out should be clinically evaluated. Diagnosis requires just a few minutes: vaginal pH testing (VVC = acidic, ≤4.5, unlike BV), a KOH wet-mount microscopy slide (reveals Candida hyphae or pseudohyphae immediately), or — for recurrent or treatment-resistant cases — a fungal culture that identifies the exact species and its antifungal susceptibility. Identifying the species matters: non-albicans VVC will not respond to fluconazole, requiring targeted alternatives including boric acid vaginal suppositories.

Screening guidance

Who should get tested for vaginal yeast infection?

Because vaginal yeast infection is usually silent, the CDC and U.S. Preventive Services Task Force recommend routine screening for the groups most likely to have it — not just people with symptoms.

  1. 1

    First episode of vaginal itching or discharge

    Anyone experiencing intense vaginal itching, burning, or thick white discharge for the first time should see a clinician before self-treating. BV, trichomoniasis, chlamydia, and gonorrhea all produce overlapping symptoms — antifungals do not treat any of these conditions, and treating the wrong diagnosis delays appropriate care. A pH test and KOH slide take minutes and eliminate guesswork.

  2. 2

    Recurrent episodes (4 or more per year — RVVC)

    Recurrent vulvovaginal candidiasis requires a confirmed fungal culture with species identification. Non-albicans species — particularly <em>C. glabrata</em> and <em>C. tropicalis</em> — do not form pseudohyphae visible on KOH microscopy, test negative on standard wet-mount, and are intrinsically resistant to fluconazole. Culture-guided therapy is essential; without it, treatment will fail. RVVC also warrants evaluation for underlying triggers: diabetes, immune suppression, hormonal contraception, and antibiotic patterns.

  3. 3

    People with diabetes or immune suppression

    Elevated blood glucose feeds <em>Candida</em> growth directly. People with type 1, type 2, or undiagnosed prediabetes experience more frequent, more severe, and harder-to-treat yeast infections. People with HIV, those on chemotherapy, or those on long-term high-dose corticosteroids face elevated risk from immune impairment. Clinical evaluation and management of the underlying condition is as important as antifungal treatment.

  4. 4

    Symptoms that don't clear with OTC treatment within one week

    If itching or discharge persists or returns within two weeks of completing OTC antifungal treatment, a clinical evaluation is needed. The three most likely explanations are: (1) the original diagnosis was wrong (BV or an STI instead of VVC); (2) the <em>Candida</em> species is resistant to azole antifungals; (3) an underlying predisposing condition (diabetes, immunosuppression, hormonal factor) is sustaining the infection. A fungal culture with susceptibility testing answers all three questions.

  5. 5

    Pregnant people

    Yeast infections are more common during pregnancy because elevated estrogen increases vaginal glycogen, providing enhanced fuel for <em>Candida</em> growth. Pregnant people should always be evaluated before treating — and should use only the 7-day topical azole regimen (miconazole or clotrimazole). Oral fluconazole is generally avoided in pregnancy, particularly in the first trimester, due to observational data suggesting possible adverse fetal outcomes at repeated or high doses. Untreated infection can be transmitted to the newborn during delivery.

  6. 6

    Whenever an STI cannot be ruled out

    If you have had a new sexual partner, unprotected sex, or any potential STI exposure, a vaginal yeast infection is not a safe self-diagnosis. Burning on urination and unusual discharge can also be signs of chlamydia, gonorrhea, or trichomoniasis — none of which antifungals will treat. A clinician can test for STIs and VVC simultaneously in a single visit, ruling out the more serious possibility.

Symptoms

What are the symptoms of vaginal yeast infection?

Most vaginal yeast infections produce noticeable symptoms — the intense vulvar itch is characteristic and hard to miss. Mild <em>Candida</em> colonization without overgrowth can be truly asymptomatic; a positive culture in the absence of any symptoms is not diagnostic of VVC and does not require treatment. A positive lab culture combined with symptoms confirms the diagnosis. Symptoms in VVC typically appear rapidly — often within days — following an identifiable trigger such as completing a course of antibiotics, starting a new hormonal contraceptive, or a period of elevated blood sugar. There is no fixed incubation period as in an STI; the infection is an overgrowth event, not a new acquisition. That's exactly why testing matters — you can have it, pass it on, and never feel a thing.

Vaginal and vulvar symptoms

  • Intense itching of the vagina and vulva — often the most distressing and prominent symptom
  • Burning sensation, especially during urination or during sexual intercourse
  • Redness and swelling of the vulva (erythema and edema)
  • Thick, white, clumpy discharge with the texture and appearance of cottage cheese — usually odorless or with a mild yeasty scent
  • Watery or slightly white discharge in milder cases (not all VVC produces the classic thick discharge)
  • Vaginal rash; in severe cases, fissures or cracked skin on the vulvar surface

Distinguishing features — what VVC does NOT typically cause

  • Strong or fishy odor — that pattern points to bacterial vaginosis (BV), which has elevated vaginal pH and needs antibiotics
  • Frothy, yellow-green, or gray discharge — more characteristic of trichomoniasis or BV, not yeast
  • Sores, ulcers, or blisters on the vulva or vagina — those suggest herpes or syphilis, not VVC
  • Vaginal pH above 4.5 — VVC maintains normal acidic pH (≤4.5); elevated pH suggests BV or trichomoniasis and should prompt a different workup

Symptoms overlap significantly with bacterial vaginosis and trichomoniasis, and can also mimic chlamydia or gonorrhea (burning on urination). A clinician can distinguish VVC from these conditions quickly with a pH test and a KOH wet-mount microscopy slide — treating the wrong condition wastes time and may allow a real STI to go undetected.

Left untreated

Why vaginal yeast infection is worth catching early

Treated early, vaginal yeast infection clears with antibiotics and causes no lasting harm. Left untreated, it can climb into the reproductive tract and beyond:

Recurrent vulvovaginal candidiasis (RVVC)

Defined as four or more confirmed episodes per year, RVVC affects approximately 5–8% of women of reproductive age and significantly impairs quality of life and sexual function. RVVC often signals an underlying trigger — uncontrolled or undiagnosed diabetes, immune suppression, hormonal contraception, repeated antibiotic courses — and frequently involves a non-albicans <em>Candida</em> species (particularly <em>C. glabrata</em>) that does not produce pseudohyphae on KOH preparation and will not respond to standard fluconazole therapy. A fungal culture with antifungal susceptibility testing is essential before choosing a management regimen.

Severe vulvar inflammation and skin breakdown

Persistent or repeated yeast infections can cause significant skin breakdown, fissuring, and secondary bacterial superinfection of the vulvar skin. Severe VVC — characterized by extensive erythema, edema, excoriation, and fissuring — does not respond adequately to 1–3 day OTC courses; a 7–14 day topical azole course or two doses of oral fluconazole (150 mg, 72 hours apart) is the step-up regimen per CDC guidelines. In very severe cases, a brief course of low-potency topical corticosteroid may be added to reduce inflammation.

Treatment-resistant non-albicans VVC

<em>Candida glabrata</em> and <em>C. tropicalis</em> are intrinsically less susceptible to azole antifungals and are responsible for a growing proportion of recurrent and treatment-resistant VVC. A culture identifying a non-albicans species explains why OTC or prescription fluconazole has failed. Boric acid 600 mg intravaginal suppositories daily for 14 days is the preferred treatment for fluconazole-resistant non-albicans VVC — it achieves remission in approximately 70–80% of cases. Nystatin vaginal suppositories are an alternative. Patients should not switch OTC antifungals hoping for a different result; a culture is the necessary next step.

Missed concurrent STI

The most consequential complication of VVC is not the infection itself but the diagnostic error of treating a presumed yeast infection while an STI goes undetected. Chlamydia and gonorrhea are frequently asymptomatic in the cervix but can progress to pelvic inflammatory disease (PID), tubal damage, and infertility if not treated. Trichomoniasis shares discharge and itching symptoms with VVC. Any person with VVC symptoms who has STI risk factors should have STI testing alongside VVC evaluation.

U.S. data

How common is vaginal yeast infection in the U.S.?

Vaginal candidiasis is extremely common across all demographics. Approximately 75% of women will have at least one confirmed episode in their lifetime; 40–45% will experience two or more. Approximately 5–8% of reproductive-age women develop recurrent VVC (4+ confirmed episodes per year), a condition that significantly impairs quality of life. VVC rates are highest during pregnancy and in women with uncontrolled diabetes or HIV. Non-albicans Candida species account for a growing proportion of cases, particularly in recurrent and treatment-resistant presentations.

1.40M
Estimated U.S. clinical visits for VVC annually (2023)
~75%
of women experience at least one VVC episode in their lifetime; ~45% will have two or more

Where you test and what it costs vary by location — see the by-location links below for vaginal yeast infection testing where you live. Source: CDC Vaginal Candidiasis Data; Sobel et al., New England Journal of Medicine; ACOG Practice Bulletin.

How testing works

How a vaginal yeast infection test works

Vaginal yeast infection is detected with a nucleic-acid amplification test (NAAT) — the most accurate method — on a urine sample or a swab. You can do it at a lab, a clinic, or at home.

When to test

Evaluate when symptoms appear. A first episode, a recurrent pattern (4+ per year), a case that is not responding to OTC therapy, or any case where an STI cannot be excluded should be assessed by a clinician. Diagnosis is made by vaginal pH testing, KOH wet-mount microscopy for <em>Candida</em> hyphae and pseudohyphae, and fungal culture for recurrent or treatment-resistant cases. Fewer than one-third of women who self-treat for a presumed yeast infection actually have one — clinical testing removes all guesswork.

After treatment

Do not self-treat if you have never had a clinician-confirmed yeast infection before, if your symptoms differ from your usual pattern, or if you may have been exposed to an STI. BV, trichomoniasis, chlamydia, and gonorrhea all cause vaginal discomfort and burning — and antifungals are completely ineffective against all of them.

Vaginal pH test First-line filter
Sample
Vaginal secretion on pH paper
Results
Immediate (same visit)

Normal vaginal pH is ≤4.5 in VVC, distinguishing it from BV (pH typically >4.5) and trichomoniasis (pH typically >4.5). A simple, inexpensive, immediately informative first filter. An elevated pH in a patient assuming she has a yeast infection should redirect the workup toward BV or trichomoniasis. pH paper is available at most clinics and pharmacies.

KOH wet-mount microscopy CDC-preferred confirmatory
Sample
Vaginal swab
Results
Same visit (immediate)

A potassium hydroxide preparation dissolves vaginal epithelial cells, revealing <em>Candida</em> hyphae or pseudohyphae under a microscope. This is the CDC-preferred confirmatory test for vaginal candidiasis — immediate in-office results. Sensitivity approximately 65–85% for <em>C. albicans</em>. Note: <em>C. glabrata</em> does not produce pseudohyphae, so a negative KOH in a symptomatic recurrent patient should prompt fungal culture, not a second OTC treatment.

Fungal culture with species identification Required for recurrent / resistant cases
Sample
Vaginal swab sent to microbiology lab
Results
2–5 days (species ID may take longer)

Recommended for recurrent (4+ episodes/year) or treatment-resistant VVC. The culture identifies the exact <em>Candida</em> species and can include antifungal susceptibility testing (MIC). Non-albicans species — <em>C. glabrata</em>, <em>C. tropicalis</em>, <em>C. krusei</em> — are frequently azole-resistant and require targeted alternatives (boric acid, nystatin). This test is the necessary step when OTC treatment has failed. Self-pay cost: ~$40–$100 at a lab.

Clinical exam and patient history First step
Sample
In-office assessment (pelvic exam)
Results
Same visit

A clinician reviews symptom characteristics (onset, triggers, discharge appearance, odor), risk factors (recent antibiotics, diabetes, pregnancy, immunosuppression), and sexual history. A consistent history combined with classic presentation, normal pH, and positive KOH microscopy is sufficient for diagnosis without sending a culture. However, history alone without objective testing over-diagnoses VVC in roughly 65% of cases.

Molecular vaginal panel (NAAT)
Sample
Vaginal swab (self- or clinician-collected)
Results
1–3 days

Some commercial NAAT panels (e.g., BD MAX Vaginal Panel) detect Candida species, BV-associated bacteria, and Trichomonas vaginalis simultaneously from a single swab. Highly sensitive and specific; increasingly available at private labs and as at-home kits. Useful when the diagnosis is uncertain or when ruling out multiple conditions simultaneously is desired. Does not replace culture for antifungal susceptibility testing in resistant cases.

What it costs: Clinical exam with pH test and wet-mount: ~$25–$120; OTC antifungal creams or suppositories (miconazole, clotrimazole, tioconazole): ~$10–$20 at any pharmacy; single-dose oral fluconazole 150 mg (generic Diflucan): ~$5–$15 with a prescription; fungal culture with species ID: ~$40–$100 at a CLIA-certified lab. Free or low-cost diagnosis and treatment at health departments, Title X family-planning clinics, and federally qualified health centers (FQHCs) on a sliding-scale basis for uninsured patients. Clinician evaluation and prescription treatments (fluconazole, butoconazole, terconazole, boric acid with prescription) covered by most ACA-compliant plans when medically indicated; OTC antifungals may be covered with a clinician's prescription under some plans.

If your result is positive

How is vaginal yeast infection treated?

Vaginal yeast infections are cured with antifungal medications. Uncomplicated VVC responds to a single 150 mg oral dose of fluconazole (generic Diflucan) or a 1–7 day course of OTC topical antifungal cream or suppository. Both approaches achieve negative cultures in approximately 80–90% of treated uncomplicated cases. The choice of treatment should account for pregnancy status, recurrence history, and whether a non-albicans species is suspected or confirmed.

Treat partners

Routine partner treatment is not recommended for uncomplicated episodes — VVC is not sexually transmitted. A male partner with penile candidiasis symptoms (redness, itching, rash on the glans — balanitis) should apply OTC topical antifungal cream (clotrimazole or miconazole) to the affected area for 7 days. Female partners in same-sex relationships who also have symptoms may benefit from concurrent evaluation. For couples with recurrent ping-pong episodes, joint evaluation is reasonable.

In pregnancy

Yeast infections are more frequent during pregnancy due to elevated estrogen and increased vaginal glycogen. <strong>Only topical azole therapies are recommended in pregnancy</strong> — specifically miconazole or clotrimazole, 7-day course. Oral fluconazole is generally avoided during pregnancy: observational studies have suggested a possible association between repeated first-trimester fluconazole exposure and adverse fetal outcomes (including cardiac septal defects); topical therapy is equally effective and eliminates this risk. All pregnant patients with VVC are classified as 'complicated VVC' regardless of symptom severity.

Re-test after treatment

A test of cure is not needed after a single uncomplicated episode that resolves fully within one week of completing treatment. Return for evaluation if symptoms persist beyond 2 weeks, recur within a month, or if you experience 4 or more episodes in a year — that pattern warrants a fungal culture, species identification, susceptibility testing, and a discussion of 6-month suppressive maintenance therapy.

Treatment & online care

Watch for: Topical azoles may cause localized burning or irritation at the application site, particularly in inflamed tissue — this usually diminishes within a day or two. Oral fluconazole can cause mild nausea, headache, or abdominal discomfort; serious side effects are rare at the single 150 mg dose. Boric acid suppositories may cause a mild watery vaginal discharge, local irritation, or a sensation of warmth — these are expected and not cause for stopping treatment. Boric acid is toxic if swallowed — store safely away from children and pets.

Prevention

How to prevent vaginal yeast infection

  • Prophylactic fluconazole when taking antibiotics

    If you reliably develop a yeast infection following antibiotic courses, ask your clinician about a single prophylactic dose of fluconazole (150 mg) taken at the start or end of the antibiotic treatment. This is a CDC-supported strategy for women with recurrent antibiotic-triggered VVC. It does not interfere with the antibiotic's effectiveness. Avoiding unnecessary antibiotic prescriptions and choosing narrow-spectrum agents when possible further reduces risk.

  • Manage blood glucose

    Elevated blood glucose directly promotes <em>Candida</em> overgrowth by providing an enhanced nutrient environment. Women with diabetes or prediabetes who experience frequent yeast infections should work with their clinician to optimize glycemic control. Reducing HbA1c often decreases VVC frequency more than any other single intervention. For those without a diabetes diagnosis, frequent yeast infections can be a presenting symptom of undiagnosed prediabetes — fasting glucose or HbA1c testing is worthwhile.

  • Wear breathable underwear and change out of damp clothing promptly

    Cotton underwear wicks moisture away from the vulva; synthetic fabrics trap warmth and humidity in which <em>Candida</em> thrives. Change promptly out of wet swimwear or damp workout clothing, and avoid prolonged time in tight-fitting pants that hold heat and moisture against the perineum. While this alone will not prevent all episodes, reducing chronic vulvovaginal warmth and humidity removes a consistent environmental trigger.

  • Avoid douching and scented vaginal products

    Douching disrupts the vaginal microbiome, removes protective <em>Lactobacillus</em>, raises pH, and significantly increases the risk of both BV and secondary VVC. Scented soaps, bubble baths, feminine sprays, and wipes applied internally or near the vaginal opening can cause irritation and microbiome disruption. The vagina is self-cleaning and requires no internal washing — use warm water only on the external vulva.

  • Suppressive therapy for recurrent VVC

    For women with RVVC (4+ confirmed episodes per year), CDC guidelines recommend an induction course followed by 6 months of maintenance oral fluconazole 150 mg once weekly — approximately 70–90% remain recurrence-free during the maintenance period. Vaginal lactobacillus probiotics show mixed evidence in clinical trials — some reduction in recurrence in specific populations — and are safe to try alongside established preventive measures, though not yet endorsed as standard of care by CDC or ACOG.

  • Get the right diagnosis before every treatment

    The most effective prevention of wasted treatment and delayed diagnosis is clinical confirmation before using any antifungal — especially for first episodes or atypical presentations. Treating a presumed yeast infection that is actually BV with an OTC antifungal exposes you to unnecessary medication while the BV progresses; treating a presumed yeast infection that is actually chlamydia or gonorrhea allows the STI to spread or ascend to the upper reproductive tract. A pH test and KOH slide at any clinic take minutes.

Who is most at risk

Who is most at risk for vaginal yeast infection?

Anyone who is sexually active can contract vaginal yeast infection, but certain groups face significantly higher risk — and should test more frequently.

Antibiotic use
Antibiotics are the single most common identifiable trigger for VVC. They eliminate the protective <em>Lactobacillus</em> species that keep vaginal pH low and <em>Candida</em> in check. <em>Candida</em> is a fungus, unaffected by antibacterial agents, and can overgrow rapidly once the competing bacterial flora is cleared. Broad-spectrum antibiotics (amoxicillin-clavulanate, fluoroquinolones, tetracyclines) carry the highest risk. A prophylactic single dose of fluconazole at the start or end of an antibiotic course is a CDC-supported strategy for women who reliably develop VVC after antibiotics.
Approximately 28–33% of women develop VVC during or immediately after antibiotic courses
Pregnancy
Elevated estrogen during pregnancy increases vaginal glycogen (a primary <em>Candida</em> energy source) and shifts the vaginal epithelium in ways that favor <em>Candida</em> adhesion and overgrowth. Yeast infection rates are substantially higher during pregnancy than in non-pregnant women at the same age. All pregnant patients with VVC are classified as 'complicated' requiring a 7-day topical treatment course.
VVC is estimated to occur in approximately 10–20% of pregnancies; even higher rates in the third trimester
Diabetes mellitus and prediabetes
Elevated blood glucose is a direct growth medium for <em>Candida</em>. Women with poorly controlled type 1 or type 2 diabetes experience more frequent, more severe, and harder-to-treat VVC. Even mild or undiagnosed prediabetes can be a driver of recurrent episodes. Optimizing glycemic control often reduces VVC frequency as effectively as antifungal maintenance — making blood sugar management a primary intervention for women with RVVC and any glucose dysregulation.
Women with diabetes have approximately 2× higher VVC prevalence than non-diabetic controls
Immune suppression
A weakened immune system — from HIV infection, chemotherapy, hematopoietic stem cell transplantation, solid-organ transplantation, or long-term high-dose corticosteroid use — impairs the T-cell–mediated defense against mucosal <em>Candida</em> colonization. Immunocompromised individuals often experience more frequent, more severe, or treatment-resistant VVC. In people with advanced HIV (CD4 count < 200), VVC can be recurrent and difficult to control without immune reconstitution on antiretroviral therapy.

Why it matters

Why STD testing matters

Find vaginal yeast infection testing
  • VVC symptoms — itching, discharge, burning on urination — overlap closely with bacterial vaginosis, trichomoniasis, chlamydia, and gonorrhea. The right diagnosis ensures you treat the right condition; antifungals do nothing for BV or STIs, and treating incorrectly can mask a serious infection.
  • Fewer than one-third of women who self-treat for a presumed yeast infection actually have one — a vaginal pH test and KOH wet-mount microscopy take minutes in any clinic and remove all diagnostic uncertainty.
  • A first episode or a recurrent pattern (4+ times per year) requires clinical evaluation to confirm the <em>Candida</em> species; non-albicans species are resistant to standard fluconazole and require different targeted treatment — including boric acid for fluconazole-resistant cases.
  • Getting an accurate diagnosis also protects against missing a concurrent STI: chlamydia, gonorrhea, and trichomoniasis can all cause vaginal discomfort and will not be cleared by antifungals.

Browse by location

Vaginal yeast infection testing by state & city

Jump to local vaginal yeast infection testing — clinics and labs, prices and county rates — in your state or a popular city, or explore another test.

Popular cities

Other STD tests

Keep reading

More on vaginal yeast infection

Deeper guides from our editorial library on vaginal yeast infection and related topics.

Living with vaginal yeast infection

Questions to ask your provider about vaginal yeast infection

Vaginal yeast infection is common, treatable, and nothing to be ashamed of — millions of Americans are diagnosed every year. The most useful next step after a positive result (or before a first test) is a direct conversation with a clinician. Here are the questions that matter most:

  • Is my vaginal yeast infection test result definitive, or do I need a confirmatory test?
  • What treatment options are available to me, and how long until I'm no longer contagious?
  • Should I notify my recent partners, and can your office help me do that confidentially?
  • How soon can I re-test to confirm the infection has cleared?
  • Are there other STIs I should test for at the same visit?
  • Can this affect my fertility, pregnancy, or long-term health if left untreated?

Good to Know

Vaginal yeast infection testing FAQs

Common questions about vaginal yeast infection and vaginal yeast infection testing, answered.

Is a vaginal yeast infection an STI?

No. A vaginal yeast infection is caused by an overgrowth of <em>Candida</em> — a fungus that normally lives in the vagina, gut, and skin — not by a pathogen transmitted through sexual contact. You can develop a yeast infection without any sexual activity, and it is not classified as a sexually transmitted disease by the CDC. Sexual activity can occasionally disrupt vaginal flora and trigger an episode, and a partner can rarely be affected, but the underlying mechanism (endogenous microbiome imbalance) is fundamentally different from STI transmission. Treatment of sexual partners is not routinely recommended.

Yeast infection vs. BV vs. trichomoniasis — how do I tell the difference?

These three conditions all cause vaginal discomfort and discharge, but each has a distinctive clinical fingerprint. VVC: intense vulvar itch, thick white cottage-cheese discharge, no odor (or mild yeasty scent), normal vaginal pH ≤4.5. BV: mild itch or none, thin gray-white watery discharge, fishy odor (especially after sex or during menstruation), elevated pH >4.5 — needs antibiotics, not antifungals. Trichomoniasis: frothy, yellow-green discharge, odor, elevated pH >4.5, often causes more pronounced burning and redness — also needs antibiotics (metronidazole or tinidazole), not antifungals. Because treatments don't overlap, getting the right diagnosis before treating is essential. A clinician can distinguish all three in a single visit with a pH test and wet-mount microscopy.

OTC vs. prescription antifungal — which is better for a yeast infection?

For an uncomplicated yeast infection with a classic pattern, OTC topical azoles (miconazole, clotrimazole, tioconazole) and prescription oral fluconazole 150 mg are equally effective — both achieve negative cultures in approximately 80–90% of treated uncomplicated cases. OTC topicals are available immediately without a prescription but must be applied correctly for 1–7 days depending on the product; they can degrade latex condoms and diaphragms. Oral fluconazole is a single-pill convenience option requiring a prescription in the U.S. (approximately $5–$15 generic) and is avoided in pregnancy. Prescription-only topicals (butoconazole, terconazole) and boric acid suppositories are reserved for cases that fail OTC treatment or involve non-albicans species confirmed by culture. Never switch between multiple OTC products hoping for a different result — if OTC treatment has failed, a culture and clinician evaluation are needed.

How long does a yeast infection take to clear?

With appropriate treatment, symptoms typically begin improving within 24–48 hours and fully resolve within 3–7 days. Single-dose oral fluconazole may take up to 72 hours to produce noticeable relief because tissue levels must build before the drug reaches adequate antifungal concentrations at the vaginal mucosa. OTC topical creams or suppositories often provide faster local symptom relief (burning and itching may ease within hours of application) but must be used for the full prescribed duration — 1, 3, or 7 days depending on the product — even if symptoms improve early. If symptoms have not meaningfully improved after one week, or return within two weeks, see a clinician — either the diagnosis was wrong or the <em>Candida</em> species is azole-resistant.

Why do I keep getting yeast infections?

Recurrent vulvovaginal candidiasis (RVVC — defined as 4 or more confirmed episodes per year) affects approximately 5–8% of women and usually signals an underlying factor sustaining the imbalance. Common drivers include: uncontrolled or undiagnosed blood sugar elevation (diabetes, prediabetes); immune suppression (HIV, chemotherapy, high-dose steroids); high-dose estrogen (hormonal contraceptives or hormone therapy); repeated antibiotic courses; and — critically — a non-albicans <em>Candida</em> species such as <em>C. glabrata</em> or <em>C. tropicalis</em> that is intrinsically resistant to fluconazole. A clinician should order a fungal culture with species ID and susceptibility testing, evaluate for underlying causes, and discuss a 6-month suppressive maintenance regimen to break the recurrence cycle.

Why do antibiotics cause yeast infections?

Antibiotics eliminate not just the target pathogenic bacteria but also the protective <em>Lactobacillus</em> species that normally dominate the vaginal microbiome, keep pH acidic, and produce hydrogen peroxide and lactic acid that inhibit <em>Candida</em> overgrowth. When lactobacilli are depleted, <em>Candida</em> — a fungus completely unaffected by antibacterial drugs — rapidly expands to fill the ecological niche. Broad-spectrum antibiotics (amoxicillin-clavulanate, fluoroquinolones, clindamycin) carry the highest risk. Approximately 28–33% of women develop VVC during or immediately after antibiotic treatment. If you reliably develop a yeast infection after antibiotics, ask your clinician about a single prophylactic dose of fluconazole — this is a CDC-recognized strategy for reducing antibiotic-triggered VVC.

Is it safe to treat a yeast infection during pregnancy?

Yes — yeast infections are more common during pregnancy due to higher estrogen levels and increased vaginal glycogen, and treating them is safe and recommended. The only regimen approved for use during pregnancy is a 7-day course of topical vaginal antifungal: miconazole or clotrimazole, applied intravaginally each night for 7 days. Oral fluconazole is generally avoided during pregnancy — observational studies have raised concern about a possible association between repeated first-trimester fluconazole exposure and adverse fetal outcomes, including cardiac septal defects, though absolute risk estimates remain debated. Topical therapy is equally effective and eliminates this concern. Untreated VVC can transmit <em>Candida</em> to the newborn during delivery, causing oral thrush or diaper rash, so treatment before delivery is worthwhile.

Can men get yeast infections from a partner?

Yes, though it is uncommon. A male partner can develop penile candidiasis (balanitis) — symptoms include redness, itching, burning, and a rash or white patches on the glans penis — with an estimated risk of approximately 15% after unprotected sex with a partner who has an active vaginal yeast infection. Most cases in male partners resolve with 7 days of OTC topical antifungal cream (clotrimazole or miconazole) applied to the affected area. Men who are uncircumcised, have diabetes, or are immunocompromised are at meaningfully higher risk of symptomatic penile candidiasis. Routine treatment of male partners when only the female partner has symptoms is not recommended by CDC or ACOG guidelines.

Can I have sex during a yeast infection?

It is generally advisable to abstain from sex until treatment is complete and symptoms have fully resolved. Intercourse during active VVC can worsen vulvar irritation and mechanical inflammation, and you can transmit <em>Candida</em> to a partner (though at relatively low rates). If you are using oil-based topical antifungal creams or vaginal suppositories, these degrade latex condoms and diaphragms — reducing their effectiveness as contraception and STI prevention. Oral fluconazole does not interfere with latex barriers. Resuming sex once you are symptom-free is safe.

What is boric acid for yeast infections, and does it work?

Boric acid is a naturally occurring antifungal compound used as an intravaginal suppository (600 mg daily for 14 days) for two specific situations: (1) confirmed non-albicans <em>Candida</em> infections (such as <em>C. glabrata</em>) that are resistant or poorly responsive to standard azoles, and (2) recurrent VVC that has not responded adequately to fluconazole maintenance. It is recommended in CDC STI Treatment Guidelines and ACOG guidance as an alternative for these resistant or recurrent cases, with studies showing remission rates of approximately 70–80% in fluconazole-resistant infections. Boric acid is NOT a first-line treatment for uncomplicated VVC, is <strong>NOT safe during pregnancy</strong> (embryotoxic — must be avoided), and is for intravaginal use only — boric acid is toxic if ingested. It requires clinician guidance, not OTC self-selection.

How is a vaginal yeast infection diagnosed?

A clinician checks vaginal pH with a simple pH strip — VVC shows normal acidic pH (≤4.5), which immediately helps distinguish it from BV (typically pH >4.5) and trichomoniasis (typically pH >4.5). A KOH wet-mount follows: potassium hydroxide is added to a vaginal swab sample on a glass slide, dissolving epithelial cells and revealing <em>Candida</em> hyphae, pseudohyphae, or budding yeast under a microscope — results are immediate and available in the same office visit. For recurrent or treatment-resistant cases, a fungal culture (sent to the microbiology lab, results in 2–5 days) identifies the exact <em>Candida</em> species and allows antifungal susceptibility testing — critical because non-albicans species will not respond to fluconazole and require different targeted therapy.

Can I have a yeast infection and an STI at the same time?

Yes — and this is a genuinely important clinical concern. A yeast infection does not protect against or rule out a concurrent STI. Chlamydia and gonorrhea are frequently asymptomatic in the cervix while a vaginal yeast infection is producing prominent itching and discharge, meaning the STI is easily missed while the VVC gets treated. Trichomoniasis symptoms overlap closely with VVC. If you have any risk factors for an STI — a new partner, unprotected sex, or exposure to someone with a known STI — it is worthwhile testing for STIs at the same visit, even when VVC symptoms are prominent. A clinician can test for VVC, BV, trichomoniasis, chlamydia, and gonorrhea in a single visit.

Yeast infection or UTI — how do I tell the difference?

Both can cause burning on urination, but the distinguishing features are different. A yeast infection causes burning primarily during or just after urination (external vulvar burning as urine contacts inflamed skin), accompanied by intense itching, vulvar redness, and thick white discharge. A UTI (urinary tract infection) causes burning primarily <em>during</em> urination that originates internally, frequent and urgent urination with small volumes, cloudy or blood-tinged urine, and often little to no vaginal discharge or itching. A UTI requires antibiotics (trimethoprim-sulfamethoxazole, nitrofurantoin) — antifungals will not treat it. A urine dipstick or culture at any clinic distinguishes the two quickly. Some women experience both simultaneously, particularly after intercourse — in that case, both need treatment.

Editorial standards

Medically reviewed · Updated

Reviewed by Dr. Mei Chen, MD, FACOG · OB-GYN

Obstetrician-gynecologist focused on reproductive and sexual health for women — pregnancy, BV, yeast, trichomoniasis and HPV/cervical screening.

8 Sources

Clinical guidance

  1. CDC — Vaginal Candidiasis https://www.cdc.gov/fungal/diseases/candidiasis/genital/index.html
  2. CDC — STI Treatment Guidelines 2021: Vaginal Discharge (Vaginitis) https://www.cdc.gov/std/treatment-guidelines/vaginal-discharge.htm
  3. ACOG Practice Bulletin — Vaginitis in Nonpregnant Patients (2020) https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2020/01/vaginitis-in-nonpregnant-patients
  4. ACOG — Vaginitis (Patient FAQ) https://www.acog.org/womens-health/faqs/vaginitis

Data & references

  1. Ferris et al. — Over-the-counter antifungal drug misuse, Obstetrics & Gynecology (2002) https://pubmed.ncbi.nlm.nih.gov/11864668/
  2. Sobel JD — Vulvovaginal candidosis, Lancet (2007) https://pubmed.ncbi.nlm.nih.gov/17561924/
  3. MedlinePlus — Vaginal Yeast Infections https://medlineplus.gov/vaginalyeastinfections.html
  4. Office on Women's Health — Vaginal Yeast Infections https://www.womenshealth.gov/a-z-topics/vaginal-yeast-infections